Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study ...

I-Mab announced positive results from a Phase 1b study of its bispecific antibody, givastomig, which targets Claudin 18.2 and 4-1BB for treating Claudin 18.2-positive gastric cancers. The study, ...

I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy. The first patient has been dosed in a phase ...

FLOT compared to FOLFOX/XELOX as a neoadjuvant chemotherapy in locally advanced gastric cancer: Experience of two clinics. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers ...

Amgen Inc (NASDAQ:AMGN) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6). The study met its primary endpoint of overall survival ...

A Chinese-developed immunotherapy regimen could offer patients with resectable gastric cancer a new treatment option that ...

Add Yahoo as a preferred source to see more of our stories on Google. Innovent's CLN18.2-targeting ADC Takeda's $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs ...

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan ...